AMDL to Present at China-America Investment Conference
October 30 2006 - 5:00AM
PR Newswire (US)
TUSTIN, Calif. and SANTA MONICA, Calif., Oct. 30
/PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and
marketer of tests for the early detection of cancer and other
serious diseases, announced today that its CEO, Gary Dreher, will
present at the China-America Investment Conference at the Shutters
on the Beach Hotel in Santa Monica at 9 a.m. on Wednesday, Nov. 1.
The RedChip Small-Cap China-America Conference will give fund
managers, stockbrokers, analysts and private investors the
opportunity to listen to presentations from companies with
involvement in China. AMDL recently announced the acquisition of
Jade Pharmaceutical Inc. in that nation and the filing with Chinese
regulatory officials for permission to market AMDL's unique
DR-70(R) cancer test kit in the world's most populous nation.
Additional information about the conference is available at
http://www.redchip.com/ . RedChip is noted for its ability to bring
together both professional and individual small-cap investors with
superior small cap companies. "We welcome this opportunity to
explain AMDL significant recent achievements and our business
strategies as we move forward," Mr. Dreher said. About AMDL AMDL,
Inc. (AMEX:ADL), headquartered in Tustin, California, is a
theranostics company, involved in the detection and treatment of
the same disease, cancer. AMDL is the inventor, developer and
worldwide marketer through exclusive distribution agreements of the
DR-70(R) non-invasive cancer blood test, which has demonstrated its
ability to detect the presence in humans of up to 14 cancers 84
percent of the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdl.com/. Forward-Looking Statements This news release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.redchip.com/ Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024